Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06817590 · ClinicalTrials.gov registry record · Phase 1
Nucleoside Therapy in Patients With Telomere Biology Disorders
A Phase 1 study of Dyskeratosis Congenita and Telomere Biology Disorders, sponsored by Suneet Agarwal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06817590 is a Phase 1 study of Dyskeratosis Congenita and Telomere Biology Disorders that is actively recruiting participants, run by Suneet Agarwal. The registered enrollment target is 36 participants, below the 849-participant average among 7 other Dyskeratosis Congenita trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06817590, a Phase 1 study of Dyskeratosis Congenita and Telomere Biology Disorders, is actively recruiting participants, sponsored by Suneet Agarwal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders. The main questions it aims to answer are: * Is the therapy safe with tolerable side effects in patients with telomere biology disorders? * Are problems with the bone marrow or blood or lungs changed after 6 months of dC+dT treatment in patients with telomere biology disorders? Participants will: * Take study drug by mouth three times daily for 24 weeks * Make approximately 2 visits to Boston Children's Hospital during the 24 weeks: once at the beginning of treatment and once at the end of treatment. * Go to a lab for a blood draw an additional 6 times during treatment. * Have 9 phone calls with a research nurse, including one 4 weeks after treatment ends. * Keep a diary to track doses of study drug that were taken or missed.
Conditions Studied
Interventions
- DRUG deoxycytidine
- DRUG deoxythymidine
Study Locations (1)
Massachusetts
- Boston Childrens Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06817590
The ClinicalTrials.gov registry entry for NCT06817590 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 849-participant average among 7 other Dyskeratosis Congenita trials with a reported enrollment target (96% lower). The listed sponsor is Suneet Agarwal, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Dyskeratosis Congenita appearing as the primary indexed condition, and to 2 interventions - of which deoxycytidine is the first listed.
NCT06817590 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06817590 about?
NCT06817590 is a clinical study titled "Nucleoside Therapy in Patients With Telomere Biology Disorders". The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders. The main questions it aims to answer are: * Is the therapy safe with tolerable side effects in patients with telomere biology diso...
What is the current status of trial NCT06817590?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-09-29. Estimated completion is 2029-06.
What conditions does trial NCT06817590 study?
This clinical trial studies the following conditions: Dyskeratosis Congenita, Telomere Biology Disorders, Hoyeraal-Hreidarsson Syndrome, Revesz Syndrome, Telomere Biology Disorders With Bone Marrow Failure.
What interventions are being tested in trial NCT06817590?
The interventions under investigation include: deoxycytidine (DRUG), deoxythymidine (DRUG).
Who is sponsoring clinical trial NCT06817590?
This trial is sponsored by Suneet Agarwal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06817590 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyskeratosis Congenita
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
RECRUITING · Phase 2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RECRUITING · Phase 2
-
Investigation of the Genetics of Hematologic Diseases
RECRUITING
-
Cancer in Inherited Bone Marrow Failure Syndromes
RECRUITING
-
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
ACTIVE NOT RECRUITING · Phase 2
-
Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD)
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.